MCM
MYGN icon

Manchester Capital Management’s Myriad Genetics MYGN Stock Holding History

Manchester Capital Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-2,200
Closed -$46K – 646
2015
Q4 		$46K Hold
2,200
– – 0.01% 463
2015
Q3 		$46K Buy
+2,200
New +$78.1K 0.01% 438
2014
Q1 		– Sell
-1,300
Closed -$27K – 1006
2013
Q4 		$27K Sell
1,300
-900
-41% -$22.8K ﹤0.01% 692
2013
Q3 		$52K Hold
2,200
– – 0.01% 597
2013
Q2 		$59K Buy
+2,200
New +$63.8K 0.01% 551

Other funds holding MYGN

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RIM
RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Manchester Capital Management's MYGN Position: Q1 2016 in Review

Manchester Capital Management sold out of Myriad Genetics (MYGN) in Q1 2016, closing a stake of 2,200 shares — an estimated $46K sold.

Manchester Capital Management first reported a position in MYGN in Q2 2013 and held it in 5 quarters. The position peaked at $59K in Q2 2013. 233 funds tracked by Wall St. Rank hold MYGN as of Q1 2016.

  • Manchester Capital Management reported no remaining Myriad Genetics position as of Q1 2016 after selling out during the quarter.
  • Manchester Capital Management sold 2,200 Myriad Genetics shares in Q1 2016, an estimated $46K.
  • Manchester Capital Management first reported a position in Myriad Genetics in Q2 2013 and held it in 5 quarters.
  • Manchester Capital Management's Myriad Genetics position peaked at $59K in Q2 2013.
  • 233 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2016.

Based on Manchester Capital Management's 13F filing for Q1 2016, filed 4 May 2016.